Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.

doi:10.1182/blood.2019003382

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.

Blood - 25 Jun 2020

Maia Catarina, Puig Noemi, Cedena Maria-Teresa, Goicoechea Ibai, Valdes-Mas Rafael, Vazquez Iria, Chillon Maria-Carmen, Aguirre Paula, Sarvide Sarai, Gracia-Aznárez Francisco Javier, Alkorta Gorka, Calasanz Maria-Jose, Garcia-Sanz Ramon, Gonzalez Marcos, Gutierrez Norma C, Martinez-Lopez Joaquin, Perez José J, Merino Juana, Moreno Cristina, Burgos Leire, Alignani Diego, Botta Cirino, Prosper Felipe, Matarraz Sergio, Orfao Alberto, Oriol Albert, Teruel Ana-Isabel, de Paz Raquel, de Arriba Felipe, Hernandez Miguel T, Palomera Luis, Martinez Rafael, Rosiñol Laura, Mateos Maria-Victoria, Lahuerta Juan-Jose, Blade Joan, San Miguel Jesus F, Paiva Bruno

Abstract excerpt

Risk of developing myelodysplastic syndrome (MDS) is significantly increased in both multiple myeloma (MM) and monoclonal gammopathy of undetermined significance, suggesting that it is therapy independent. However, the incidence and sequelae of dysplastic hematopoiesis at diagnosis are unknown. Here, we used multidimensional flow cytometry (MFC) to prospectively screen for the presence of MDS-associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clonal Hematopoiesis

Share to Combined Modality Therapy

Share to Multiple Myeloma

Share to Myelodysplastic Syndromes

Share to Progression-Free Survival

Share to Randomized Controlled Trials as Topic

Share to Transplantation, Autologous

Source

Open in PubMed

Identifiers

PMID: 32299093
DOI: 10.1182/blood.2019003382

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.PMID 32299093Read ↗

The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.Semantic proximity Read ↗

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative NeoplasmsSemantic proximity Read ↗

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.Semantic proximity Read ↗

Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis.Semantic proximity Read ↗

Pathogenic Mutations and Atypical Flow Cytometric Findings Characterize the Majority of Unclassifiable Myelodysplastic/Myeloproliferative Neoplasms.Semantic proximity Read ↗

Response Predictors and Clonal Evolution during Thalidomide Therapy in Myelodysplastic Neoplasms with Increased BlastsSemantic proximity Read ↗

Profiling Myelodysplastic Syndromes by Mass Cytometry Demonstrates Abnormal Progenitor Cell Phenotype and DifferentiationSemantic proximity Read ↗

Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation.Semantic proximity Read ↗

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.Semantic proximity Read ↗

Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel TherapiesSemantic proximity Read ↗

Genomic Determinants and Clinical Outcomes of Second Primary Hematological Malignancies in Patients with B-cell Cancers.Semantic proximity Read ↗

The Significance of Detecting an Unusual Myeloblast Immunophenotype in a Presumptive Clinical Diagnosis of Myelodysplastic Syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.